Center-Authored Papers

Filters: Author is Shou, Yaping  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Young Adult
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G et al..  2011.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.. Blood. 117(4):1141-5. Abstract
United States
Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E et al..  2009.  Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(25):4204-10. Abstract
Tretinoin
Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley TA, Yang T, Epping MT, Shou Y, Pogosova-Agadjanyan E et al..  2009.  The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.. Blood. 114(15):3299-308. Abstract
Treatment Outcome
Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E et al..  2009.  Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(25):4204-10. Abstract
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G et al..  2011.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.. Blood. 117(4):1141-5. Abstract
Time Factors
Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E et al..  2009.  Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(25):4204-10. Abstract
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G et al..  2011.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.. Blood. 117(4):1141-5. Abstract
Specimen Processing Core Facility
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract
Shared Resources
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract
Safety
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract
Pyrimidines
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G et al..  2011.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.. Blood. 117(4):1141-5. Abstract
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract
Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E et al..  2009.  Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(25):4204-10. Abstract
Proto-Oncogene Proteins c-abl
Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley TA, Yang T, Epping MT, Shou Y, Pogosova-Agadjanyan E et al..  2009.  The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.. Blood. 114(15):3299-308. Abstract
Protein-Tyrosine Kinases
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract
Protein Kinase Inhibitors
Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley TA, Yang T, Epping MT, Shou Y, Pogosova-Agadjanyan E et al..  2009.  The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.. Blood. 114(15):3299-308. Abstract
Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E et al..  2009.  Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(25):4204-10. Abstract
Prognosis
Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley TA, Yang T, Epping MT, Shou Y, Pogosova-Agadjanyan E et al..  2009.  The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.. Blood. 114(15):3299-308. Abstract
Piperazines
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract
Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E et al..  2009.  Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(25):4204-10. Abstract
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G et al..  2011.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.. Blood. 117(4):1141-5. Abstract
Neoplastic Stem Cells
Oehler VG, Guthrie KA, Cummings CL, Sabo K, Wood BL, Gooley TA, Yang T, Epping MT, Shou Y, Pogosova-Agadjanyan E et al..  2009.  The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.. Blood. 114(15):3299-308. Abstract
Mutation
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract
Hughes T, Saglio G, Branford S, Soverini S, Kim D-W, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E et al..  2009.  Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(25):4204-10. Abstract
Middle Aged
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G et al..  2011.  Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.. Blood. 117(4):1141-5. Abstract